Karyopharm Therapeutics Inc. (KPTI) Total liabilities 2016–2025
Karyopharm Therapeutics Inc. (KPTI) total liabilities at each fiscal year-end, per SEC filings.
$401.3MFY2025 · since FY2016: $18.1M → $401.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $401.3M | +14.5% |
| FY2024 | $350.4M | -7.0% |
| FY2023 | $376.6M | +0.5% |
| FY2022 | $374.8M | -2.6% |
| FY2021 | $385.0M | +46.7% |
| FY2020 | $262.5M | +7.1% |
| FY2019 | $245.2M | +55.2% |
| FY2018 | $158.0M | +210.9% |
| FY2017 | $50.8M | +180.2% |
| FY2016 | $18.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More KPTI financial trends
KPTI RevenueKPTI Net incomeKPTI Net marginKPTI Gross profitKPTI Gross marginKPTI Operating incomeKPTI Operating marginKPTI Operating cash flowKPTI Free cash flowKPTI Capital expendituresKPTI Return on equityKPTI Stock buybacksKPTI Dividends paidKPTI Total assetsKPTI Shareholders’ equityKPTI overview →